The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InRegeneron has secured FDA approval for its gene therapy Otarmeni, targeting OTOF-related hearing loss, following a record-breaking 61-day priority review process. This accelerated approval via a pilot program underscores the therapy's clinical significance, supported by CHORD trial data showing 42% of participants achieved full hearing restoration. The treatment is administered through a specialized syringe and catheter kit, with reported side effects including ear infections, nausea, and dizziness. In a strategic move to ensure patient access, Regeneron will provide the therapy free of charge to eligible individuals within the United States. While the free-access initiative may impact immediate financials, the rapid regulatory milestone reinforces Regeneron's leadership in the precision medicine sector. Investors are now focused on the long-term commercial scalability of this genetic research platform.